What did @haleighweaver5 actually say?
Honestly, very little. The transcript is essentially filler audio: "We're going to go. That is getting us. We're going to go." There are no medical claims, no dosing advice, no before-and-after statistics, and no specific assertions about semaglutide or tirzepatide beyond what the hashtags imply. The video appears to be a transformation montage set to audio, with the substance communicated visually and through hashtag framing rather than spoken words.
This matters because the claim being made is implicit. By tagging content with #semaglutide, #tirzepatide, and #weightlosstransformation, the creator is associating their physical transformation with GLP-1 receptor agonist use. That is the message, even if it is never spoken aloud. Viewers with 129,000 views are reading that subtext clearly. So the fact-check has to engage with what the content implies, not just what was literally said.
Does the science back this up?
The general premise, that GLP-1 receptor agonists produce meaningful weight loss, is well-supported. The specific claim, that a personal transformation seen in this video is attributable to these drugs, is unverifiable. But the underlying pharmacology is solid enough to take seriously.
Semaglutide (Wegovy) at 2.4mg weekly produced an average 14.9% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). Tirzepatide outperformed that benchmark in the SURMOUNT-1 trial, with participants on the highest dose losing an average of 22.5% of body weight over 72 weeks (Jastreboff et al., 2022, New England Journal of Medicine). These are not trivial numbers. For context, older obesity medications rarely broke 5-8% average weight loss in trials.
So if this creator used one of these medications and lost significant weight, the science does support that outcome as plausible. What science cannot confirm is the individual's specific experience, timeline, or whether other factors like diet changes or exercise contributed.
What did they get wrong (or right)?
They did not get anything technically wrong because they did not say anything technically. That is both a defense and a critique. Transformation content that implies drug-driven results without disclosing side effects, costs, eligibility criteria, or the reality that roughly a third of patients discontinue GLP-1 medications within a year due to adverse effects or access issues is doing real work on the viewer while maintaining plausible deniability.
What the hashtag framing glosses over is meaningful. Nausea affects up to 44% of semaglutide users (Davies et al., 2021, Lancet). Muscle mass loss alongside fat loss is a documented concern, with some studies suggesting 25-39% of total weight lost may come from lean mass without resistance training (Bikou et al., 2023, Nutrients). The transformation content genre rarely addresses this. Showing the result without the full picture is not a lie, but it is an incomplete story reaching 129,000 people.
What should you actually know?
If you are watching transformation content and wondering whether GLP-1 medications could work for you, here is what the research actually says. These drugs are prescription medications indicated for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. They are not cosmetic tools and they are not a quick fix. Average results from trials are exactly that, averages. Some people lose significantly more, some lose less, and some do not respond meaningfully.
Access is a real barrier. Brand-name Wegovy and Zepbound carry list prices exceeding $1,000 per month without insurance coverage. Compounded versions are available at lower cost through some telehealth platforms, but compounded drugs are not FDA-approved and are not equivalent to brand-name formulations in the ways that matter for regulatory purposes. Anyone telling you compounded semaglutide is the same product as Wegovy is overstating what the evidence allows.
Long-term data is still accumulating. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) showed semaglutide reduced major cardiovascular events by 20% in people with existing cardiovascular disease and obesity, which is a significant finding. But five and ten-year outcomes for the broader population using these drugs for weight management are not yet fully established.
The bottom line on transformation content
Hashtag-driven before-and-after content is not fact-checkable in the traditional sense because it makes its argument visually and associatively, not verbally. What we can say is that the underlying pharmacology is real, the results seen in clinical trials are clinically significant, and individual transformation videos tell you nothing reliable about what your experience would look like. Talk to a licensed clinician, review your metabolic health history, and do not make decisions based on 15-second TikToks, no matter how many views they have.